AECC's AEP100 liquid hydrogen turboprop completed a 16-minute maiden flight in Zhuzhou, producing zero carbon emissions and establishing China's lead in hydrogen aviation propulsion.
Attackers compromised CPUID's backend API and replaced download links for four popular hardware tools with malware-laden installers, infecting over 150 users across multiple countries.
Stanford HAI's annual AI Index report reveals that China has nearly closed the gap with the US on model benchmarks, generative AI adoption has outpaced the PC and internet, and AI data centers now draw enough power to run New York state.
MRI imaging and tissue analysis reveal that the middle meningeal artery hosts an organized lymphatic network responsible for brain waste removal, with implications for Alzheimer's research.
At least four bipartisan bills in the 119th Congress would create tax credits, authorize funding, and stand up USDA task forces to reduce US dependence on petroleum-derived chemicals by scaling plant-based biomanufacturing.
Shareholders of both Coursera and Udemy voted over 99% in favor of combining into a single platform serving 245 million learners, with FTC clearance already secured and closing expected in the second half of 2026.
Credo Technology pays $750M cash plus stock for Israeli silicon photonics firm DustPhotonics, targeting $500M in combined optical revenue by fiscal 2027.
Two companion trials published in Nature Medicine show oral FMT capsules raised immunotherapy response rates to 80% in lung cancer and 75% in melanoma, while reducing toxic side effects in kidney cancer.
MIT spinout Quaise Energy plans to extend its record-setting millimeter wave drilling from 118 meters to one kilometer this year, advancing a technology that could unlock superhot geothermal energy virtually anywhere on Earth.
The Servo project publishes its first crates.io release, making the Rust-native browser engine available as an embeddable library with a WebView API and a six-month LTS cycle.
The first once-weekly treatment for achondroplasia is now commercially available in the United States after Ascendis Pharma secured orphan drug exclusivity through 2033.
Bristol-based Vertical Aerospace flew its VX4 prototype from vertical takeoff into wingborne cruise on April 2, marking the third such piloted demonstration in the West and clearing the way for two-way transition trials later this year.